Verify any claim · lenz.io
Claim analyzed
Health“A research group at Kyoto University led by Professor Masanori Fukushima concluded that blood from COVID-19-vaccinated individuals contains dangerous proteins that can be transmitted to other people via blood transfusion.”
Submitted by Noble Dolphin 6d92
The conclusion
No peer-reviewed Kyoto University study has concluded that vaccinated blood contains dangerous, transmissible proteins. The claim traces to a speculative, non-peer-reviewed preprint amplified by low-credibility media outlets. While trace spike protein fragments have been detected post-vaccination, no evidence establishes they pose a transfusion risk. Real-world transfusion outcome data from the Japanese Red Cross and AABB-cited studies find no increased adverse events in recipients of vaccinated donor blood.
Based on 25 sources: 6 supporting, 11 refuting, 8 neutral.
Caveats
- The claim conflates a speculative, non-peer-reviewed preprint with an institutional 'Kyoto University research group conclusion' — no such peer-reviewed study exists.
- Detection of low-level spike protein fragments after vaccination does not establish clinical danger or transmissibility via blood transfusion; this is a non sequitur leap.
- Major blood safety organizations (Japanese Red Cross, AABB) and real-world recipient outcome studies report no increased adverse events from transfusions using vaccinated donor blood.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
The Japanese Red Cross Society is the sole provider of blood products in Japan. Vaccinated individuals are eligible to donate blood, with a waiting period of 48 hours after mRNA vaccination. There is no ban on blood donations from COVID-19 vaccinated individuals.
The proportion of anti-nucleocapsid antibodies induced by previous SARS-CoV-2 infection in blood donors has increased from previous reports; however, it was 42.8% overall. Thus, the population with infection-induced immunity is low compared with that of other countries. COVID-19 vaccines are particularly important for high-risk populations in Japan. The findings of this study will contribute to an updated safety profile, alleviate concerns regarding the safety of COVID-19 vaccines, and encourage appropriate vaccination.
Our study confirms no detrimental impact of chronic transfusions on immune response to vaccinations and adds new interesting findings, relevant ...
S-protein emerged on the surface of exosomes in the blood of the vaccinated . Fragments of vaccine-specific recombinant S-protein were found in blood specimens of 50% of vaccine recipients and were still detected three to six months later . ... Therefore, it is reasonable to assume that the additional thrombus-forming tendency noted with the mRNA-LNP vaccine could be extremely dangerous. The viral and vaccine S-protein of SARS-CoV-2 ... could attach to electro-negative glycoconjugates on the surfaces of red blood cells (RBCs), other blood cells, and endothelial cells .
Study [41 referenced in PMC article] detected S-protein on exosomes in vaccinated blood, but levels were low and no evidence of harm or transmissibility via transfusion. Clinical outcomes unchanged.
However, it has been reported worldwide that the modified mRNAs encoding spike proteins and lipid nanoparticles, which are used as drug delivery systems, not only cause thrombosis and cardiovascular disorders post vaccination, but might also cause diverse diseases involving all organs and systems, including the nervous system. Furthermore, the toxicity and pathogenicity of spike proteins may necessitate defining these proteins as nonbiological infective material. Based on these reports and the abundant evidence that has come to light in the past few years, this paper aims to draw the attention of medical professionals to the various risks associated with transfusion using blood products derived from long COVID patients or from genetic vaccine recipients.
Booster vaccination reduces the incidence of severe cases and mortality related to COVID-19, with cellular immunity playing an important role. However, little is known about the proportion of the population that has achieved cellular immunity after booster vaccination.
The researchers concluded that, 'this study provides reassuring insights into the safety of blood transfusions from donors with varying SARS-CoV-2 exposure histories. These results provide some reassurance in the context of the national prevalence of blood donor SARS-CoV-2 prior infection and vaccination. Nationally, the combined infection- and vaccination-induced SARS-CoV-2 donor seroprevalence was estimated to be 96 percent by September 2022. The findings support the continued use of blood products from vaccinated and previously infected donors, addressing patient concerns about potential risks.'
Receiving a plasma or platelet transfusion from donors who had a prior COVID-19 infection or who have been vaccinated against COVID-19 does not increase the risk of adverse outcomes, according to the results of a new study from Kaiser Permanente Northern California (KPNC). The study, published Feb. 26 in Transfusion, found no link between these transfusions and an increased risk of thrombosis, respiratory complications or hospital mortality. 'Our study is the first to link specific SARS-CoV-2 antibody data from blood donors with the patients who received their blood, and we found no evidence that patients who had received blood from a donor who had been vaccinated was affected in a negative way by that blood product,' said lead author Nareg Roubinian, MD.
During the COVID-19 pandemic, excess deaths including cancer have become a concern in Japan... some excess cancer mortalities were observed in 2021 after mass vaccination with the first and second vaccine doses, and significant excess mortalities were observed for all cancers and some specific types of cancer after mass vaccination with the third dose in 2022.
Masanori Fukushima, a retired oncologist, has made unsubstantiated claims about spike proteins in vaccinated blood posing transfusion risks, but no peer-reviewed study from Kyoto University supports this. Japanese health authorities confirm vaccinated blood is safe for donation, with no policy changes.
The Japanese preprint about the tainted blood supply is similarly speculative and alarmist. It calls for the suspension of the vaccination campaign against COVID, using the same repackaged half-truths and fictions that so many other anti-vaccine review articles spew. One of its authors, Masanori Fukushima, has already published with Seneff and McCullough. ... The claim that the spike protein or its messenger RNA can be detected for weeks or months after vaccination is based on studies where fragments were barely detectable, often trillionths of a gram, which is in keeping with our understanding of biology.
No evidence exists that blood from COVID-19-infected or vaccinated donors increases risk to transfusion recipients. Extensive studies ... The studies found: No increased risk of respiratory or thrombotic complications in recipients of plasma or platelet products from vaccinated donors. No dose-dependent relationship between the amount of antibody in donor blood and adverse outcomes. No evidence that recently vaccinated or recently infected donors posed additional risk. Take-Home Messages: No evidence exists that blood from COVID-19-infected or vaccinated donors increases risk to transfusion recipients.
Kyoto University Emeritus Professor Masanori Fukushima published an essay in the April 2024 issue of Bungei Shunju on COVID-19 vaccine aftereffects, detailing his involvement in the Vaccine Issues Research Group established in June 2023 to study vaccine-related health damages including vascular disorders and myocarditis. No direct mention of blood transfusion risks or dangerous proteins in vaccinated blood.
The paper criticizes mRNA COVID-19 vaccines as a fundamental immunological design error, linking them to widespread health damages in Japan and globally, including post-vaccination syndrome (PVS). It does not specifically address blood transfusions or transmission of dangerous proteins via blood from vaccinated individuals.
This position paper from the Vaccine Issues Research Group, associated with Professor Fukushima, addresses health issues from novel mRNA COVID-19 vaccines causing increased illnesses worldwide. It focuses on general vaccine safety concerns but does not mention blood transfusions or transmissible dangerous proteins specifically.
Furthermore, just as there is no evidence to support the transmission of COVID-19 through blood donation there is no evidence demonstrating transmission of COVID-19 vaccine components through blood donation. However, we must also acknowledge that no studies have explicitly addressed the latter. Importantly, patients should be reassured that vaccines based on mRNA technology provide instructions to build immunity against future infections and do not interact with or alter recipient DNA.
As a donor's COVID-19 vaccination status does not pose a safety risk for transfusion, it is not recorded and cannot be conveyed to hospitals, physicians, or ...
At a 2024 press conference, Professor Yasufumi Murakami referenced a preprint paper co-authored with Professor Masanori Fukushima (Kyoto University Emeritus) warning of health risks from blood transfusions from mRNA-vaccinated individuals, including blood abnormalities, immune dysfunction, and neurological complications. The paper proposes screening and regulatory measures but is not peer-reviewed.
Professor Masanori Fukushima (Kyoto University Emeritus) is part of the Vaccine Issues Research Group criticizing COVID-19 vaccine safety, listing various syndromes like thrombocytopenia and myocarditis. No specific reference to blood transfusion risks or dangerous proteins transmissible via vaccinated blood.
Kyoto University Emeritus Professor Masanori Fukushima urges review of vaccine death reports on the Ministry of Health website, emphasizing medical origins in patient care. The article discusses general vaccine harms but not blood transfusions or transmissible proteins.
The preprint by Fukushima et al. (2024) remains unpublished in a peer-reviewed journal as of 2026 and has been criticized for lacking empirical data on transmissible proteins in vaccinated blood. Mainstream health authorities like WHO and CDC find no evidence supporting transfusion risks from vaccinated donors.
At a press conference for bereaved families held on 25 November, Dr. Masanori Fukushima, Professor Emeritus at Kyoto University, warned about Covid injection harms... Dr. Masanori Fukushima has published several articles on biomedical research and translational medicine, and, as well being Professor Emeritus at Kyoto University, works in the Translational Research Informatics Centre Foundation for Biomedical Research and Innovation, Kobe, Japan.
A preprint by Japanese researchers including Kyoto University Emeritus Professor Masanori Fukushima warns of risks from mRNA-vaccinated blood transfusions, citing potential transmission of mRNA, lipid nanoparticles, or spike proteins leading to thrombosis and organ issues. It calls for screening protocols and legal labeling of blood sources. Note: This is a blog summarizing the preprint; the lead author is from Asahikawa Medical University.
Research involving institutions like Asahikawa Medical University and Kyoto Okamoto Memorial Hospital (associated with Fukushima) identifies risks in blood from mRNA-vaccinated donors, including platelet reduction, thrombosis, abnormal red blood cells, and spike protein toxicity. Recommends strict screening for spike proteins and vaccine components before transfusion.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
Expert review
How each expert evaluated the evidence and arguments
Expert 1 — The Logic Examiner
To prove the claim, the evidence must show (i) a Kyoto University research group led by Masanori Fukushima (ii) concluded vaccinated donors' blood contains dangerous proteins (iii) that are transmissible via transfusion; however, the supporting items mainly show a speculative preprint/media summaries and at most detect low-level spike fragments/exosomal spike (Sources 4-6, 19, 24-25) without logically establishing “dangerous” or “transmissible,” while credible reporting and transfusion-outcome/policy evidence contradict the asserted risk and note no peer‑reviewed Kyoto University study supports the transfusion-danger conclusion (Sources 1, 9, 11-12, 22, plus Source 5 explicitly noting no evidence of harm/transmissibility). Therefore the inference from “some spike-related material can be detected” to “dangerous proteins transmissible via transfusion” is a non sequitur and the claim's institutional/provenance framing (“Kyoto University group led by Fukushima concluded…”) is not established by the evidence, making the claim false.
Expert 2 — The Context Analyst
The claim omits that the alleged “Kyoto University-led research group conclusion” appears to come from a speculative, non–peer-reviewed preprint and media amplification rather than an empirical Kyoto University study, and it elides that even sources discussing spike/exosome detection describe low levels without evidence of harm or transfusion transmissibility while real-world transfusion outcome studies and blood-system policies find no increased recipient risk (11,12,5,9,1). With full context, the statement gives a materially misleading impression that Kyoto University research established a demonstrated, transfusion-transmissible danger in vaccinated blood, which is not supported and is contradicted by higher-quality evidence on transfusion safety.
Expert 3 — The Source Auditor
High-authority, independent sources on transfusion practice and outcomes—Japanese Red Cross (Source 1) and AABB summarizing a peer‑reviewed Transfusion study (Source 9)—state vaccinated donors are eligible and recipient outcomes are not worsened by receiving blood products from vaccinated donors, while Japan Times (Source 11) reports no peer‑reviewed Kyoto University study supports Fukushima's transfusion-risk claims and McGill OSS (Source 12) characterizes the underlying preprint-style argument as speculative and lacking empirical evidence of transmissible harm. The only “support” for the specific allegation of a Kyoto University-led group concluding transmissible dangerous proteins comes from low-reliability, non-independent amplifiers (Sources 19, 24, 25) and a preprint platform (Source 6) that does not establish validated findings, so the trustworthy evidence refutes the claim's substance and does not credibly support the asserted Kyoto University conclusion.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Source 19 (Independent Web Journal) documents that Professor Masanori Fukushima, Kyoto University Emeritus, co-authored a preprint warning of health risks — including blood abnormalities, immune dysfunction, and neurological complications — from transfusions using mRNA-vaccinated blood, while Source 6 (Sciety) and Source 4 (PubMed Central) provide corroborating scientific basis by confirming that spike proteins emerge on exosomes in vaccinated blood and may cause thrombosis and multi-organ pathology, supporting the core premise that dangerous proteins exist in vaccinated blood. Furthermore, Source 24 (Earth Review) and Source 25 (Thailand Medical News) confirm that Fukushima was part of a research group that formally called for screening protocols to prevent transmission of these proteins via transfusion, establishing that the claim accurately reflects the conclusions published by that group.
You're trying to upgrade a speculative, non–peer-reviewed warning into a Kyoto University “research group” conclusion, but your key provenance is a low-credibility media echo chamber (Source 19, IWJ; Source 24, Earth Review; Source 25, Thailand Medical News) while credible reporting explicitly says there is no peer‑reviewed Kyoto University study supporting Fukushima's transfusion-risk claims (Source 11, The Japan Times) and critiques the preprint as alarmist and lacking empirical evidence of transmissible harmful material (Source 12, McGill OSS; Source 22, LLM Background Knowledge). And even if you cite detection of tiny spike fragments on exosomes (Source 4, PubMed Central; Source 5, PubMed), you commit a non sequitur by leaping from “detectable” to “dangerous and transmissible via transfusion,” a leap contradicted by real-world recipient outcome data and blood-system policy finding no increased adverse outcomes from vaccinated donors (Source 9, AABB; Source 1, Japanese Red Cross).
Argument against
The motion is false because no credible evidence shows a Kyoto University research group led by Masanori Fukushima “concluded” vaccinated blood contains transmissible dangerous proteins; rather, reporting notes his transfusion-risk claims are unsubstantiated and not backed by any peer‑reviewed Kyoto University study (Source 11, The Japan Times), and the main write-up pushing transfusion alarms is a speculative preprint-style argument criticized for lacking empirical data and remaining unpublished (Source 12, McGill OSS; Source 22, LLM Background Knowledge). In contrast, real-world transfusion safety evidence and blood-system policy explicitly support vaccinated donor eligibility and find no increased adverse outcomes in recipients of blood from vaccinated donors (Source 1, Japanese Red Cross; Source 9, AABB).
Your reliance on Source 11 (The Japan Times) is critically undermined by Source 19 (Independent Web Journal), which directly documents a 2024 press conference where Fukushima's co-author explicitly referenced their jointly authored preprint warning of transfusion risks — proving the claim that such conclusions were formally published and publicly asserted by the group, regardless of peer-review status. You also commit a logical fallacy of shifting the goalposts: the motion claims Fukushima's group "concluded" these risks exist, and Sources 24 and 25 confirm they did exactly that in a formal preprint calling for screening protocols, while your counter-sources (Source 1, Source 9) only demonstrate that mainstream bodies disagree — which does not erase the fact that Fukushima's group reached and published those conclusions.